Insulin COVID-19 outcomes
November 2026
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
He−235%3.35 · 3.08–3.64death53,030 (all patients)
He−163%2.63 · 2.36–2.93death53,030 (all patients)
He−277%3.77 · 3.31–4.29death53,030 (all patients)
Dinoi−55%1.55 · 1.06–2.26deathcase-control study
Luk−186%2.86 · 1.09–7.48death385 (n)679 (n)
Luk−2099%21.99 · 4.85–99.60ventilation385 (n)679 (n)
Luk−995%10.95 · 5.50–21.80ICU385 (n)679 (n)
Pazoki9%0.91 · 0.50–1.65death53 (n)340 (n)
Pazoki−7%1.07 · 0.44–2.71severe case53 (n)340 (n)
Matviichuk−43%1.43 · 1.14–1.66PASC53/8371/152
Matviichuk19%0.81 · 0.57–1.07PASC36/94191/375
Nowak−84%1.84 · 1.22–2.79death/hosp.1,021 (n)4,803 (n)
Soff−28%1.28 · 1.10–1.48PASC1,218 (n)6,212 (n)
00.511.52+